1 Min Read
Oct 10 (Reuters) - Astellas Pharma Inc-
* U.S. FDA grants fast track designation to Astellas for development of gilteritinib in relapsed or refractory acute myeloid leukemia Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.